Dogwood Therapeutics, Inc. (DWTX) vs INmune Bio, Inc. (INMB)

A side-by-side comparison of Dogwood Therapeutics, Inc. and INmune Bio, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

Compare

Total return — DWTX vs INMB

growth of $100 · dividends reinvested · last 6y
DWTX -99.6% (-60.8%/yr)INMB -79.0% (-22.9%/yr)INMB compounded faster over this window
Log scale — wide-divergence pair
01101001kStart $100202120222023202420252026$0$21
DWTX INMB

DWTX vs INMB: by the numbers

  • •DWTX is the larger company ($51M vs $51M market cap).
  • •Both run net losses; DWTX's is the smaller (0.00% vs -91866.00% net margin).

Metrics side by side

Valuation

MetricDWTXINMB
P/B ratio0.752.51

Profitability

MetricDWTXINMB
Gross margin0.00%100.00%
Operating margin0.00%-61738.00%
Net margin0.00%-91866.00%
ROE-52.72%-90.44%
ROIC-38.04%-96.37%

Growth (annualized)

MetricDWTXINMB
Total return CAGR (5Y)-58.44%-36.88%

Frequently asked

How have DWTX and INMB total returns compared?
Over the past 5 years, DWTX delivered -58.44% and INMB delivered -36.88% annualized total return. Past performance doesn't predict future results.

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.